{
  "id": "everyday#risk_safety_5e0f5b84",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "with drug use disorders; and self-harm/suicide and other disability (1). The resources that have been provided significant emotional or medically unexplained to tackle the huge burden of MNS disorders are complaints (7). The priority conditions were selected as insufficient, inequitably distributed and inefficiently they represented a large burden in terms of mortality, used (2). The result is a large treatment gap, more morbidity or disability; have high economic costs; than 75% in many countries with low and lower and are often associated with violations of human middle incomes (1,3). The stigma and discrimination rights. Additionally, as part of the scaling-up strategy associated with MNS conditions further exacerbates of mhGAP in countries, derivative products based on the issues and creates additional barriers for people to mhGAP guidelines were developed. seek and access care (4). In keeping with WHO’s practice of regularly monitoring To reduce the treatment gap and to enhance the new and emerging evidence, a new edition of the capacity of countries to respond to the growing mhGAP guideline is now timely. The first and second challenge, the World Health Organization (WHO) editions of the mhGAP guideline, and derivative developed the Mental Health Gap Action Programme products, have been used by more than 100 countries (mhGAP) (5). mhGAP has provided health planners, and translated into more than 20 languages over the policy-makers and donors with a set of clear and past 11 years. There has been a rapid expansion in the coherent activities and programmes for scaling up care use of the guideline since 2015. A systematic review for MNS disorders. An essential component of mhGAP found that 33 studies reported use of mhGAP in 2017 is the evidence-based guideline for MNS disorders (11). This review was recently updated, with authors identified as conditions of high priority for low- and noting a substantial increase in use of mhGAP with 162 middle-income countries (LMICs). new studies published since 2018 (12). mhGAP was launched in 2008 (5) and the first set The widespread use of mhGAP has important of WHO recommendations was published in 2010 implications, from direct clinical care to policy and as part of the mhGAP intervention guide (2,6). The system-wide changes. The use of mhGAP also affects recommendations were updated and published in the other health systems strengthening efforts – for 2015 mhGAP guideline (7,8), followed a year later by the example, it has had an influence on the WHO model list updated intervention guide in 2016 (9). These evidence- of essential medicines (known as the EML) (13). 2",
  "gloss_vi": "With drug use disorders; and tự hại/tự sát and other disability (1). the resources that have been provided significant emotional or medically unexplained to tackle the huge burden of mns disorders are complaints (7).",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety"
    ],
    "life_topics": [
      "study"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn with drug use disorders; and self-harm/suicide and other disability (1). The resources that have been provided significant emotional or medically unexplained to tackle the huge burden of MNS disorders are complaints (7). The priority conditions were selected as insufficient, inequitably distributed and inefficiently they represented a large burden in terms of mortality, used (2). The result is a large treatment gap, more morbidity or disability; have high economic costs; than 75% in many countries with low and lower and are often associated with violations of human middle incomes (1,3). The stigma and discrimination rights. Additionally, as part of the scaling-up strategy associated with MNS conditions further exacerbates of mhGAP in countries, derivative products based on the issues and creates additional barriers for people to mhGAP guidelines were developed. seek and access care (4). In keeping with WHO’s practice of regularly monitoring To reduce the treatment gap and to enhance the new and emerging evidence, a new edition of the capacity of countries to respond to the growing mhGAP guideline is now timely. The first and second challenge, the World Health Organization (WHO) editions of the mhGAP guideline, and derivative developed the Mental Health Gap Action Programme products, have been used by more than 100 countries (mhGAP) (5). mhGAP has provided health planners, and translated into more than 20 languages over the policy-makers and donors with a set of clear and past 11 years. There has been a rapid expansion in the coherent activities and programmes for scaling up care use of the guideline since 2015. A systematic review for MNS disorders. An essential component of mhGAP found that 33 studies reported use of mhGAP in 2017 is the evidence-based guideline for MNS disorders (11). This review was recently updated, with authors identified as conditions of high priority for low- and noting a substantial increase in use of mhGAP with 162 middle-income countries (LMICs). new studies published since 2018 (12). mhGAP was launched in 2008 (5) and the first set The widespread use of mhGAP has important of WHO recommendations was published in 2010 implications, from direct clinical care to policy and as part of the mhGAP intervention guide (2,6). The system-wide changes. The use of mhGAP also affects recommendations were updated and published in the other health systems strengthening efforts – for 2015 mhGAP guideline (7,8), followed a year later by the example, it has had an influence on the WHO model list updated intervention guide in 2016 (9). These evidence- of essential medicines (known as the EML) (13). 2 With drug use disorders; and tự hại/tự sát and other disability (1). the resources that have been provided significant emotional or medically unexplained to tackle the huge burden of mns disorders are complaints (7)."
}